BCAT1 knockdown-mediated suppression of melanoma cell proliferation and migration is associated with reduced oxidative phosphorylation.

Abstract

Malignant melanoma has a high mutational rate. As a result, resistance to current therapies is common. Consequently, there is an unmet medical need to develop novel therapies. Recent data suggest that branched-chain amino acid transaminase 1 (BCAT1) is overexpressed in multiple cancers, and such overexpressed BCAT1 is necessary for individual cancer progression. Therefore, BCAT1 appears to be a good target in cancer treatment. Additionally, because its expression in healthy tissues is highly restricted in adults and is limited to the brain, ovary, and placenta, BCAT1 is especially an ideal target in cancer therapies. Currently, the function of BCAT1 in malignant melanoma has not been demonstrated. Therefore, we investigated the role of BCAT1 in the proliferation and migration of malignant melanomas using human samples and mouse malignant B16 melanoma cell line. Our data showed that BCAT1 was overexpressed in malignant melanoma tissues both in humans and mice. Besides, BCAT1 knockdown suppressed melanoma cell proliferation and migration, which was associated with reduced oxidative phosphorylation. Collectively, our data indicate that BCAT1 is a promising therapeutic target for the treatment of malignant melanomas.

• Authors: Bingxia Zhang, Fang Xu, Kaijuan Wang, Mengduan Liu, Jinxia Li, Qianwei Zhao, Liya Jiang, Zhendong Zhang, Yamei Li, Huiping Chen, Jianying Zhang, Xiaolei Tang, Jintao Zhang
• Journal: American journal of cancer research (Am J Cancer Res) Vol. 11 Issue 6 Pg. 2670-2683 ( 2021) ISSN: 2156-6976 [Print] United States
• PMID: 34249421 (Publication Type: Journal Article)
• Copyright: AJCR Copyright © 2021.